AcceleRET-MTC
11 Apr 2022
Trial Summary
A study to evaluate the efficacy and safety of pralsetinib compared with SOC treatment (cabozantinib or vandetanib) for participants with RET (rearranged during transfection)-mutant MTC who have not previously received a SOC MultiKinase Inhibitor (MKI) therapy.
Acronym:
AcceleRET-MTC
ACTRN/NCT /ethics:
NCT04760288
Scientific title:
A Phase III, Randomized, Open-Label Study of Pralsetinib Versus Standard of Care for Treatment of RET-Mutated Medullary Thyroid Cancer.
Sponsor / Cooperative group:
Hoffmann-La Roche
Trial & Patient Characteristics
| Cancer Type | Other |
|---|---|
| Trial Type | Treatment |
| Phase | Phase III |
| Age Range | 12 years and older |
| Sex | All |
| Tumour Stream | Thyroid |
| Cancer Stage | Locally Recurrent or Locally Advanced; Metastatic or Widespread |
| Anticipated Start Date | 2022-07-01 |
| Anticipated End Date | 2028-04-15 |
Participating Hospitals
| Hospital | Icon Cancer Centre Adelaide |
|---|---|
| Clinical Trial Coordinator | Sue Yeend |
| sue.yeend@icon.team | |
| Phone | 08 8292 2204 |
| Principal Investigator | Dr Gonzalo Tapia Rico |
| Recruitment Status | Not Yet Recruiting |